Storkpharm Investment Spółka z Ograniczoną Odpowiedzialnością (KRS 0000744107, NIP 5732903862) is a Polish company, headquartered in Częstochowa, Śląskie voivodeship. Storkpharm Investment operates in: Manufacture of pharmaceutical preparations (PKD 21.20.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since August 13, 2018. Storkpharm Investment's most recently reported net revenue was 378.2 K PLN for 2024.
Negative equity
Negative equity in 2 of 5 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Storkpharm Investment
Identity
- Name
- Storkpharm Investment Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- August 13, 2018
- Registry status as of
- November 21, 2025
- Latest entry
- October 29, 2025
- Founding act
- 01.08.2018 R. NOTARIUSZ IZABELA MAJOCHA, KANCELARIA NOTARIALNA, NOTARIUSZE ADAM SADOWSKI, IZABELA MAJOCHA S.C. W CZĘSTO…
Articles of association history (3)
- August 1, 2018: 01.08.2018 R. NOTARIUSZ IZABELA MAJOCHA, KANCELARIA NOTARIALNA, NOTARIUSZE ADAM SADOWSKI, IZABELA MAJOCHA S.C. W CZĘSTOCHOWIE UL. DĄBROWSKIEGO NR 15 LOK.14-15, REP. A NR, 3754/2018
- May 21, 2019: 21.05.2019 R. NOTARIUSZ IZABELA MAJOCHA, KANCELARIA NOTARIALNA W CZĘSTOCHOWIE UL. DĄBROWSKIEGO NR 15 LOK.14-15, REP. A NR 2616/2019, ZMIENIONO § 6 UST.2 PKT 9, DODANO § 6 UST.2 PKT 10 UMOWY
- March 15, 2021: 15.03.2021R. REP. A NR 834/2021, NOTARIUSZ MAGDALENA KRÓLAK-POJNAR KANCELARIA NOTARIALNA W CZĘSTOCHOWIE, ALEJA JANA PAWŁA II 76/78, ZMIENIONO § 2 I § 7.4
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. PIASTOWSKA, 235, 42-202, CZĘSTOCHOWA, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- CZĘSTOCHOWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-80815-49444-CFRTR-31
- Coordinates
- 50.8052, 19.1183approx.
Risk and payment profile - Storkpharm Investment
Credibility rating
25.4 / 100
Poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
29
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany właścicieli. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
5
5/8 yrs
Board changes
3
3/8 yrs
PKD changes
0
0/8 yrs
Name changes
1
1/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: E (25/100)
Trend: deteriorating (-9.7 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2019–2024
Current: 619.9 K PLN
Safe: 86.8 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Storkpharm Investment
Founded
August 13, 2018
7 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
CZĘSTOCHOWA
ŚLĄSKIE
Primary PKD
21.20.Z
Manufacture of pharmaceutical preparations
Share capital
5.0 K PLN
50 shares total
Shareholders
1
shareholder
Board
2 people
Filed years
5 years
2019–2024 · profitable: 3/5
Registry entries
28
latest: October 29, 2025
Risk signals
Revenue
378.2 K PLN
2024
Net profit
-186.5 K PLN
2024
Assets
5.0 M PLN
2024
Equity
-752.7 K PLN
2024
EBITDA
235.2 K PLN
2024
Valuation
194.7 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Storkpharm Investment.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) – the only Polish manufacturer of biosynthetic human insulin – closed 2025 with revenue of PLN 235.9m and EBITDA of PLN 53.82m (an 18.72% margin), but a net loss of around PLN 16.4m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6m), driven by international expansion (Malaysia at ~PLN 100m a year) and a contract to produce the insulin analogue glargine. Yifan Pharmaceutical controls 31.65% of the capital indirectly.
News
Celon Pharma 2025: record PLN 244m revenue, but the net loss deepens to PLN 79.4m – the 2026 outlook hinges on Salmex in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin near Łomianki) closed 2025 with consolidated revenue of PLN 244.34m (+17.9% YoY), EBITDA of PLN 21.42m (+42%) and a deeper net loss of PLN 79.36m (versus PLN 34.45m a year earlier). The wider loss reflects spending on the innovative GLP-1 segment. The generics segment grew 15.3% and accounts for 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of the capital and 68.2% of voting rights through Glatton sp. z o.o.
